Literature DB >> 9593783

A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.

N Nagvekar1, A M Moody, P Moss, I Roxanis, J Curnow, D Beeson, N Pantic, J Newsom-Davis, A Vincent, N Willcox.   

Abstract

Myasthenia gravis (MG) is caused by helper T cell-dependent autoantibodies against the muscle acetylcholine receptor (AChR). Thymic epithelial tumors (thymomas) occur in 10% of MG patients, but their autoimmunizing potential is unclear. They express mRNAs encoding AChR alpha and epsilon subunits, and might aberrantly select or sensitize developing thymocytes or recirculating peripheral T cells against AChR epitopes. Alternatively, there could be defective self-tolerance induction in the abundant maturing thymocytes that they usually generate. For the first time, we have isolated and characterized AChR-specific T cell clones from two MG thymomas. They recognize extracellular epitopes (alpha75-90 and alpha149-158) which are processed very efficiently from muscle AChR. Both clones express CD4 and CD8alpha, and have a Th-0 cytokine profile, producing IL-4 as well as IFN-gamma. They are restricted to HLA-DP14 and DR52a; expression of these minority isotypes was strong on professional antigen-presenting cells in the donors' tumors, although it is generally weak in the periphery. The two clones' T cell receptor beta chains are different, but their alpha chain sequences are very similar. These resemblances, and the striking contrasts with T cells previously cloned from non-thymoma patients, show that thymomas generate and actively induce specific T cells rather than merely failing to tolerize them against self antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593783      PMCID: PMC508815          DOI: 10.1172/JCI2068

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Mapping the main immunogenic region and toxin-binding site of the nicotinic acetylcholine receptor.

Authors:  T Barkas; A Mauron; B Roth; C Alliod; S J Tzartos; M Ballivet
Journal:  Science       Date:  1987-01-02       Impact factor: 47.728

2.  Properties of a panel of monoclonal antibodies which react with the human T cell antigen receptor on the leukemic line HPB-ALL and a subset of normal peripheral blood T lymphocytes.

Authors:  A W Boylston; J Borst; H Yssel; D Blanchard; H Spits; J E de Vries
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

Review 3.  The spectrum of diseases associated with thymoma. Coincidence or syndrome?

Authors:  J V Souadjian; P Enriquez; M N Silverstein; J M Pépin
Journal:  Arch Intern Med       Date:  1974-08

4.  Sequence analysis of the human alpha beta T-cell receptor CDR3 region.

Authors:  P A Moss; J I Bell
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients.

Authors:  N E Gilhus; J A Aarli; B Christensson; R Matre
Journal:  J Neuroimmunol       Date:  1984-11       Impact factor: 3.478

6.  Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus or thymoma.

Authors:  Y Fujii; Y Monden; K Nakahara; J Hashimoto; Y Kawashima
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

7.  Myasthenia gravis: immunohistological heterogeneity in microenvironmental organization of hyperplastic and neoplastic thymuses suggesting different mechanisms of tolerance breakdown.

Authors:  M Chilosi; A Iannucci; L Fiore-Donati; G Tridente; M Pampanin; G Pizzolo; M Ritter; M Bofill; G Janossy
Journal:  J Neuroimmunol       Date:  1986-05       Impact factor: 3.478

8.  Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody.

Authors:  M Dardenne; W Savino; J F Bach
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

9.  Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin.

Authors:  C L Williams; V A Lennon
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3.

Authors:  J P Johnson; T Meo; G Riethmüller; D J Schendel; R Wank
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

View more
  13 in total

1.  A role for CD36 in the regulation of dendritic cell function.

Authors:  B C Urban; N Willcox; D J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Potent immunostimulatory dendritic cells can be cultured in bulk from progenitors in normal infant and adult myasthenic human thymus.

Authors:  M E Hill; D J Ferguson; J M Austyn; J Newsom-Davis; H N Willcox
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

3.  Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma).

Authors:  Y Kadota; M Okumura; S Miyoshi; S Kitagawa-Sakakida; M Inoue; H Shiono; Y Maeda; T Kinoshita; R Shirakura; H Matsuda
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

4.  Immune-mediated diseases and immunodeficiencies associated with thymic epithelial neoplasms.

Authors:  Muhammad Rizwan Khawaja; Robert P Nelson; Nicholas Miller; Sunil S Badve; Elizabeth Loehrer; Magdalena Czader; Susan M Perkins; Kenneth Kesler; Patrick J Loehrer
Journal:  J Clin Immunol       Date:  2012-01-08       Impact factor: 8.317

Review 5.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

6.  Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

Authors:  A Meager; M Wadhwa; P Dilger; C Bird; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

7.  Serum cytokine and chemokine profiles in patients with myasthenia gravis.

Authors:  A Uzawa; N Kawaguchi; K Himuro; T Kanai; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

8.  Immunological system status and the appearance of respiratory system disturbances in thymectomized patients.

Authors:  Paweł Krawczyk; Marta Adamczyk-Korbel; Robert Kieszko; Elzbieta Korobowicz; Janusz Milanowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

9.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population.

Authors:  Liang Sun; Yunxiao Meng; Yanchen Xie; Hua Zhang; Zheng Zhang; Xiaoxia Wang; Bin Jiang; Wei Li; Yao Li; Ze Yang
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.